Zhiyuan Xu1, Scott Ellis1, Cheng-Chia Lee1, Robert M Starke1, David Schlesinger2, Mary Lee Vance3, M Beatriz Lopes4, Jason Sheehan5. 1. Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia. 2. Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia; Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia. 3. Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia; Department of Internal Medicine, University of Virginia, Charlottesville, Virginia. 4. Division of Neuropathology, University of Virginia, Charlottesville, Virginia. 5. Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia; Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia. Electronic address: jsheehan@virginia.edu.
Abstract
PURPOSE: To investigate the safety and effectiveness of stereotactic radiosurgery (SRS) in patients with a silent corticotroph adenoma (SCA) compared with patients with other subtypes of non-adrenocorticotropic hormone staining nonfunctioning pituitary adenoma (NFA). METHODS AND MATERIALS: The clinical features and outcomes of 104 NFA patients treated with SRS in our center between September 1994 and August 2012 were evaluated. Among them, 34 consecutive patients with a confirmatory SCA were identified. A control group of 70 patients with other subtypes of NFA were selected for review based on comparable baseline features, including sex, age at the time of SRS, tumor size, margin radiation dose to the tumor, and duration of follow-up. RESULTS: The median follow-up after SRS was 56 months (range, 6-200 months). No patients with an SCA developed Cushing disease during the follow-up. Tumor control was achieved in 21 of 34 patients (62%) in the SCA group, compared with 65 of 70 patients (93%) in the NFA group. The median progression-free survival (PFS) was 58 months in the SCA group. The actuarial PFS was 73%, 46%, and 31% in the SCA group and was 94%, 87%, and 87% in the NFA group at 3, 5, and 8 years, respectively. Silent corticotroph adenomas treated with a dose of ≥17 Gy exhibited improved PFS. New-onset loss of pituitary function developed in 10 patients (29%) in the SCA group, whereas it occurred in 18 patients (26%) in the NFA group. Eight patients (24%) in the SCA group experienced worsening of a visual field deficit or visual acuity attributed to the tumor progression, as did 6 patients (9%) in the NFA group. CONCLUSION: Silent corticotroph adenomas exhibited a more aggressive course with a higher progression rate than other subtypes of NFAs. Stereotactic radiosurgery is an important adjuvant treatment for control of tumor growth. Increased radiation dose may lead to improved tumor control in SCA patients.
PURPOSE: To investigate the safety and effectiveness of stereotactic radiosurgery (SRS) in patients with a silent corticotroph adenoma (SCA) compared with patients with other subtypes of non-adrenocorticotropic hormone staining nonfunctioning pituitary adenoma (NFA). METHODS AND MATERIALS: The clinical features and outcomes of 104 NFA patients treated with SRS in our center between September 1994 and August 2012 were evaluated. Among them, 34 consecutive patients with a confirmatory SCA were identified. A control group of 70 patients with other subtypes of NFA were selected for review based on comparable baseline features, including sex, age at the time of SRS, tumor size, margin radiation dose to the tumor, and duration of follow-up. RESULTS: The median follow-up after SRS was 56 months (range, 6-200 months). No patients with an SCA developed Cushing disease during the follow-up. Tumor control was achieved in 21 of 34 patients (62%) in the SCA group, compared with 65 of 70 patients (93%) in the NFA group. The median progression-free survival (PFS) was 58 months in the SCA group. The actuarial PFS was 73%, 46%, and 31% in the SCA group and was 94%, 87%, and 87% in the NFA group at 3, 5, and 8 years, respectively. Silent corticotroph adenomas treated with a dose of ≥17 Gy exhibited improved PFS. New-onset loss of pituitary function developed in 10 patients (29%) in the SCA group, whereas it occurred in 18 patients (26%) in the NFA group. Eight patients (24%) in the SCA group experienced worsening of a visual field deficit or visual acuity attributed to the tumor progression, as did 6 patients (9%) in the NFA group. CONCLUSION: Silent corticotroph adenomas exhibited a more aggressive course with a higher progression rate than other subtypes of NFAs. Stereotactic radiosurgery is an important adjuvant treatment for control of tumor growth. Increased radiation dose may lead to improved tumor control in SCA patients.
Authors: Or Cohen-Inbar; Zhiyuan Xu; Cheng-Chia Lee; Chin-Chun Wu; Tomáš Chytka; Danilo Silva; Mayur Sharma; Hesham Radwan; Inga S Grills; Brandon Nguyen; Zaid Siddiqui; David Mathieu; Christian Iorio-Morin; Amparo Wolf; Christopher P Cifarelli; Daniel T Cifarelli; L Dade Lunsford; Douglas Kondziolka; Jason P Sheehan Journal: J Neurooncol Date: 2017-09-14 Impact factor: 4.130
Authors: Ajay Chatrath; Jacob Kosyakovsky; Parantap Patel; Jungeun Ahn; Mazin Elsarrag; Lena C Young; Angela Wu; Jennifer D Sokolowski; Davis Taylor; John A Jane; M Beatriz S Lopes Journal: Pituitary Date: 2022-10-19 Impact factor: 3.599
Authors: Laura Flores; Richard Sleightholm; Beth Neilsen; Michael Baine; Andjela Drincic; William Thorell; Nicole Shonka; David Oupicky; Chi Zhang Journal: Case Rep Oncol Date: 2019-02-08
Authors: M E Torregrosa-Quesada; A García-Martínez; A Sánchez-Barbie; S Silva-Ortega; R Cámara; C Fajardo; C Lamas; I Aranda; A Pico Journal: J Endocrinol Invest Date: 2021-01-21 Impact factor: 4.256
Authors: Richard A Hickman; Jeffrey N Bruce; Marc Otten; Alexander G Khandji; Xena E Flowers; Markus Siegelin; Beatriz Lopes; Phyllis L Faust; Pamela U Freda Journal: Neuropathol Appl Neurobiol Date: 2020-12-20 Impact factor: 8.090